Yuki Otani

Eli Lilly and Company

Poster(s):

• P4371 - Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn’s Disease in Phase 2 and 3 Studies
  Tuesday, October 29, 2024

  10:30 AM – 4:00 PM ET